CRBP-300-196.png
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
October 18, 2018 16:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediatorsĀ in airway macrophages from cystic fibrosis patientsCystic fibrosis is a life-threatening...